Targiniq is a drug owned by Purdue Pharma Lp. It is protected by 24 US drug patents filed from 2014 to 2018. Out of these, 5 drug patents are active and 19 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 30, 2025. Details of Targiniq's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Targiniq's patents.

Latest Legal Activities on Targiniq's Patents

Given below is the list of recent legal activities going on the following patents of Targiniq.

Activity	Date	Patent Number
Critical Events for all Patents
Expire Patent Critical	01 Jul, 2024	US9345701
Expire Patent Critical	22 Apr, 2024	US9283221
Expire Patent Critical	22 Apr, 2024	US9283216
Maintenance Fee Reminder Mailed Critical	15 Jan, 2024	US9345701
Expire Patent Critical	04 Dec, 2023	US9168252
Expire Patent Critical	27 Nov, 2023	US9161937
Maintenance Fee Reminder Mailed Critical	06 Nov, 2023	US9283216
Maintenance Fee Reminder Mailed Critical	06 Nov, 2023	US9283221
Expire Patent Critical	28 Aug, 2023	US9084729
Expire Patent Critical	24 Jul, 2023	US9056051

FDA has granted several exclusivities to Targiniq. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Targiniq, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Targiniq.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Targiniq's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Targiniq's generic, the next section provides detailed information on ongoing and past EP oppositions related to Targiniq patents.

Targiniq's Oppositions Filed in EPO

Targiniq has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 30, 2009, by Hexal Ag. This opposition was filed on patent number EP03720425A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP11177518A	Feb, 2018	Zentiva, k.s.	Revoked
EP11177516A	Feb, 2018	Zentiva, k.s.	Revoked
EP11177516A	Feb, 2018	Teva Pharmaceutical Industries Ltd	Revoked
EP11177518A	Feb, 2018	Teva Pharmaceutical Industries Ltd	Revoked
EP11177516A	Feb, 2018	Intas Pharmaceuticals Ltd.	Revoked
EP11177518A	Feb, 2018	Intas Pharmaceuticals Ltd.	Revoked
EP11177518A	Jan, 2018	STADA Arzneimittel AG	Revoked
EP11177516A	Jan, 2018	STADA Arzneimittel AG	Revoked
EP11177518A	Nov, 2017	G. L. Pharma GmbH	Revoked
EP11177516A	Nov, 2017	G. L. Pharma GmbH	Revoked
EP11177516A	Nov, 2017	Ethypharm	Revoked
EP11177518A	Nov, 2017	Ethypharm	Revoked
EP11177520A	Aug, 2017	Ethypharm	Revoked
EP11177520A	Aug, 2017	Intas Pharmaceuticals Ltd.	Revoked
EP11177520A	Aug, 2017	Teva Pharmaceutical Industries Ltd	Revoked
EP11177520A	Aug, 2017	G. L. Pharma GmbH	Revoked
EP11177516A	Jul, 2017	Acino Pharma AG	Revoked
EP11177518A	Jul, 2017	Acino Pharma AG	Revoked
EP11177520A	Jun, 2017	STADA Arzneimittel AG	Revoked
EP11177516A	Jun, 2017	KRKA, d.d., Novo mesto	Revoked
EP11177518A	Jun, 2017	Krka, d.d., Novo mesto	Revoked
EP11177516A	May, 2017	Glenmark Pharmaceuticals Europe Ltd	Revoked
EP11177518A	May, 2017	Glenmark Pharmaceuticals Europe Ltd	Revoked
EP11177520A	May, 2017	Glenmark Pharmaceuticals Europe Ltd	Revoked
EP11177518A	May, 2017	Hexal AG / Sandoz International GmbH	Revoked
EP11177518A	May, 2017	Develco Pharma Schweiz AG	Revoked
EP11177516A	May, 2017	Develco Pharma Schweiz AG	Revoked
EP11177516A	May, 2017	Hexal AG / Sandoz International GmbH	Revoked
EP11177520A	May, 2017	Hexal AG / Sandoz International GmbH	Revoked
EP11177520A	Apr, 2017	Acino Supply AG	Revoked
EP11177520A	Apr, 2017	KRKA, d.d., Novo mesto	Revoked
EP11177520A	Mar, 2017	Develco Pharma Schweiz AG	Revoked
EP11186168A	Oct, 2016	James Poole Limited	Opposition rejected
EP03720424A	Mar, 2016	STADA Arzneimittel AG	Revoked
EP03720424A	Mar, 2016	KRKA, d.d., Novo mesto	Revoked
EP03720424A	Mar, 2016	FRKelly	Revoked
EP03720424A	Mar, 2016	Zentiva k.s.	Revoked
EP03720424A	Mar, 2016	Develco Pharma Schweiz AG	Revoked
EP03720424A	Mar, 2016	ETHYPHARM	Revoked
EP03720424A	Mar, 2016	G. L. Pharma GmbH	Revoked
EP03720424A	Mar, 2016	Hexal AG / Sandoz International GmbH	Revoked
EP03720424A	Feb, 2016	Teva Pharmaceutical Industries Ltd	Revoked
EP03720424A	Feb, 2016	Acino Pharma AG	Revoked
EP03720424A	Dec, 2015	Actavis Group PTC ehf	Revoked
EP10011792A	Oct, 2015	Setna, Rohan P.	Granted and Under Opposition
EP10011792A	Oct, 2015	Hoffmann Eitle	Granted and Under Opposition
EP10011792A	Oct, 2015	James Poole Limited	Granted and Under Opposition
EP10011792A	Oct, 2015	Acino Pharma AG	Granted and Under Opposition
EP05730345A	Dec, 2011	Actavis group PTC ehf	Patent maintained as amended
EP05730345A	Dec, 2011	Acino Pharma AG	Patent maintained as amended
EP05730345A	Dec, 2011	Elend, Almut Susanne	Patent maintained as amended
EP03720425A	Sep, 2009	Hexal AG	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Targiniq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Targiniq's family patents as well as insights into ongoing legal events on those patents.

Targiniq's Family Patents

Targiniq has patent protection in a total of 44 countries. It's US patent count contributes only to 21.8% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Targiniq.

Full family tree

Generic Launch

About Targiniq

Targiniq is a drug owned by Purdue Pharma Lp. It is used for managing severe chronic pain when alternative treatment options are inadequate, requiring daily, around-the-clock, long-term opioid treatment. Targiniq uses Naloxone Hydrochloride; Oxycodone Hydrochloride as an active ingredient. Targiniq was launched by Purdue Pharma Lp in 2014.